Clinical Trial Update: Open-label Study of the Efficacy and Safety of VESIcare® in Patients With Overactive Bladder Symptoms [Phase 3]

View source ↗

Summary

Open-label Phase 3 study evaluating the efficacy and safety of Vesicare (solifenacin) in patients with overactive bladder; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Vesicare (solifenacin succinate)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Urinary Bladder, Overactive | Phase 3 | Status: COMPLETED